The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | MRD updates from the CASSIOPEIA trial
Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, presents findings from the CASSIOPEIA trial (NCT02541383), which now has almost seven years of follow-up data. The study highlights the strong correlation between flow cytometric and NGS methods for assessing measurable residual disease (MRD). The highest rates of MRD-negativity were observed in patients receiving daratumumab in both induction/consolidation and maintenance. Dr Corre mentions the importance of assessing MRD post-induction and optimizing induction regimens for patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
